Navigation Links
Amedica Receives CE Mark for Valeo(TM) Ceramic Spinal Implant System Incorporating CSC Technology

SALT LAKE CITY, May 4 /PRNewswire/ -- Amedica Corporation, an orthopedic implants company focused on silicon nitride ceramic technologies, announced today that it has received a CE (Conformite Europeene) mark for initial rollout of their spinal intervertebral spacers using novel CSC (cancellous-structured ceramic) technology. The CSC technology, made using Amedica's novel silicon nitride ceramic, offers a porous cancellous trabecular structure designed to promote bony fusion.

The Valeo family of ceramic spinal intervertebral spacers is intended to aid in surgical correction and stabilization of the cervical and thoracolumbar spine. These implants are designed to restore the biomechanical integrity of the anterior, middle and posterior spine, for a prolonged period of time. The Valeo family of spacers provides new functionalities compared to competing devices currently on the market and is believed to be the first family of ceramic implants available for spinal use in the world.

"Amedica's ceramic spinal spacers uniquely combine strength with improved ability for bony integration and bone-like imaging compatibility, making them a valuable alternative to currently available devices using conventional synthetic materials," said Darrel Brodke, M.D., Professor and Vice-Chair, Director of Spine Service, Department of Orthopaedics, University of Utah School of Medicine. "Because these implants have a combination of distinguishing features, I would expect Amedica's implants to be well received in Europe and Asia where allograft bone is not frequently used."

"Obtaining the CE mark for our Valeo CSC ceramic spinal spacers expands our ability to bring our portfolio of innovative spinal implant products to important markets in Europe, Asia and other regions of the world," said Ashok Khandkar, Ph.D., Chief Executive Officer of Amedica Corporation. "This achievement gives us the ability to begin to train physicians in Europe and other foreign markets so that more patients can benefit from our innovative implants."

About Amedica

Amedica Corporation is an emerging orthopedic implant company focused on using its silicon nitride ceramic technologies to develop and commercialize a broad range of innovative, high-performance spine and joint implants for the growing orthopedic device market. Its products currently under development include spine implants that may represent a new standard of care in the treatment of spinal injuries, diseases, and disorders based on superior durability, performance and safety.

SOURCE Amedica Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amedica Receives FDA 510(k) Clearance for Valeo(TM) Pedicle Screw System
2. Amedica Receives FDA 510(k) Clearance for Valeo(TM) Cervical Plate
3. Divergence Receives $1.2 Million in Grants, Including NSF Grant to Fund Continuing Nematode Research in Corn
4. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
5. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
6. China Medical Technologies Receives SFDA Approval for Its Bladder Cancer FISH Probe
7. Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors
8. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. Sunesis Pharmaceuticals Receives NASDAQ Notification
10. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
11. Cambrex Receives Notice Regarding NYSE Listing
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):